FDA approves first-ever treatment for patients with inoperable plexiform neurofibromas – News-Medical.Net

Image: Wikimedia Commons


The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA’s approval of AstraZeneca’s and MSD (Merck)’s submission is a major milestone for patients living with neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the body. Affecting 1 in 3,000 people of all populations equally, this announcement is the first-ever approved treatment for NF, and portends the potential for the development of treatment options for all NF patients.

Click here to read full article https://www.news-medical.net/news/20200413/FDA-approves-first-ever-treatment-for-patients-with-inoperable-plexiform-neurofibromas.aspx

Font Resize